The harmful effects of prenatal exposure to
valproate are well documented. Following a review, the Commission on Human
Medicines has recommended further restrictions to valproate use to reduce
avoidable harm which were introduced by the MHRA in January.
Please see the attached letter from Chief Medical
Officers across the UK regarding the recently announced sodium valproate safety
measures.